tailieunhanh - Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. | Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN